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BMD (5, 10). Conversely, vitamin D supplementation has been shown
to maintain or slow the rate of bone loss in older adults (11), with
even greater benefits observed in vitamin D deficient patients and/or
those with osteomalacia (12). To date however, most of the
randomised controlled trials (RCTs) with BMD as the primary endpoint
have involved combined vitamin D and calcium supplementation, and
targeted older women or men and women combined; there are few
studies in men alone (13-18).
In a 3-year clinical trial examining the effects of supplementation with
calcium citrate malate (500 mg/d) and vitamin D3 (700 IU/d) in
ambulatory men aged over 65 years, Dawson-Hughes et al (15)
reported that the mean change in femoral neck, lumbar spine, and
total body BMD was 1.2–1.8% less in the calcium-vitamin D3
supplemented group compared with placebo group. In a similar 2-
year RCT examining the effects of calcium-vitamin D3 fortified milk
(1000 mg calcium and 800 IU vitamin D3 per day) on BMD in men
aged over 50 years, Daly et al (16) reported that supplementation
was effective for slowing or stopping bone loss at the clinically
relevant hip, spine and ultra-distal radius. Among the older men (aged
>62 years) in this study, the calcium-vitamin D3 fortified milk also
prevented the age-related expansion of the medullary cavity and
slowed the loss in cortical volumetric BMD which helped to preserve
cortical area and bone strength
(polar moment of inertia) at the
mid-femur (17). This is an
important f inding because it
demonstrates that calcium-vitamin
D supplementation can have
beneficial effects on bone
structural properties and estimates
of bone strength in older adults. In
a subsequent follow-up study, the
net beneficial effects of the fortified
milk on hip and ultra-distal radius
BMD were sustained 18 months
after withdrawal of the
supplementation; there were no
lasting benefits at the lumbar spine
and bone structural properties
were not assessed (18). The
authors attributed the sustained
skeletal benefits to the
maintenance of habitual calcium
intakes above the current
recommended requirements (1000
mg/d) for older men. In summary,
the findings from these limited
studies in men indicate that 
INTRODUCTION
Vitamin D deficiency, which is commonly defined as a serum 25-
dihydroxyvitamin D [25(OH) D] level below 50 nmol/L (20 ng/ml), is a
major public health problem that is estimated to affect 1 billion people
worldwide (1). While the prevalence of vitamin D deficiency varies
according to the population studied, the highest rates of deficiency
are found among housebound and institutionalized elderly women
and men (1-4). In Australia and Europe it has been reported that up to
70 to 80% of institutionalized men living in hostels or nursing homes
have severe vitamin D deficiency [25(OH)D <25 to 30 nmol/L] (2-4). It
has also been reported that in excess of 50% of apparently healthy
older community dwelling men are vitamin D insufficient or deficient
(3). The adverse effects of vitamin D deficiency on bone health
include increased bone turnover, bone loss and an increased risk of
fracture, and in severe cases of deficiency, rickets and osteomalacia
(5). Following the discovery of vitamin D receptors in muscle tissue
(and most tissues and cells of the body), low vitamin D levels have
been shown to be consistently associated with reduced lower
extremity muscle performance and an increased risk of falling (5-8).
In this brief perspective, we review the evidence related to the effects
of vitamin D on bone mineral density (BMD), fractures, muscle
function and falls risk in elderly
men, and consider the optimal
level of serum 25(OH) D and dose
of vitamin D needed to enhance
musculoskeletal health and
function in elderly men. 
VITAMIN D AND BONE
MINERAL DENSITY
Osteoporosis is a serious and
underestimated public health
problem in men. Current figures
indicate that one in three men
compared to one in two women
aged over 60 years will suffer a
fracture due to osteoporosis (9).
Vitamin D plays a key role in the
maintenance of BMD by promoting
the absorption of calcium in the
intestines and ensuring optimal
mineralization of the bone matrix.
In older women and men, low
levels of serum 25(OH)D have
been associated with reduced
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ABSTRACT: Vitamin D deficiency is associated with a myriad of musculoskeletal disorders in the elderly, including osteoporosis,
reduced muscle function, falls and fractures. Recent scientific trials, conducted mostly in elderly or institutionalized women, indicate that
supplementation with at least 800 IU/d of vitamin D3 or a dose required to raise serum 25(OH) D levels to at least 75 nmol/L, and
approximately 1200 mg/d of calcium is most effective for improving many of these musculoskeletal and functional performance
measures. While further targeted research is still needed in elderly men, vitamin D supplementation should be considered as a safe and
low cost strategy to optimize musculoskeletal health and function in both elderly men and women.
Robin M.
Daly
Boonen et al (24) reported that only vitamin D with additional calcium
(and not vitamin D alone) was associated with a significant reduction
in hip and non-vertebral fracture risk (18% and 12%, respectively)
versus placebo/no treatment. However, Trivedi et al (25) reported a
reduction in non-vertebral fractures in ambulatory older men and
women treated with vitamin D alone. The latest meta-analysis on the
use of calcium or calcium in combination with vitamin D
supplementation to prevent fractures and reduce bone loss in people
aged 50 years and older revealed that treatment with calcium and
calcium plus vitamin D was associated with a 12% risk reduction in
fractures of all types (26). Interestingly, the treatment effect was
similar for calcium and calcium plus vitamin D (RR 0.87 vs 0.90,
P=0.63). They also reported that: i) a higher compliance (>80%) with
the supplements was associated with a greater fracture risk
reduction; ii) those with the lowest serum 25(OH)D levels tended to
have a greater risk reduction (p=0.06); iii) the treatment effect was
greatest in those whose daily calcium intake was low (<700 mg/d);
and iv) the treatment effect was best with calcium doses of >1200
mg/d or vitamin D does of >800 IU/d. Based on the above evidence, it
would appear that vitamin D and/or calcium supplementation can
reduce fracture rates in the elderly, particularly in those with low
dietary calcium and serum 25(OH)D levels. In addition, calcium and
vitamin D should be given with other osteoporosis therapies in men
with established osteoporosis (27).
VITAMIN D, MUSCLE FUNCTION AND FALLS RISK
Several large observational and prospective studies involving both
older women and men have shown that low serum 25(OH)D levels
are related to reduced muscle strength and power, accelerated loss in
muscle mass and strength, reduced gait speed, impaired balance,
and increased sway (5-7). This has been attributed, at least in part, to
the finding that specific vitamin D receptors (VDR) are present in
vitamin D and calcium supplementation, either in the form of oral
tablets or food enriched with calcium and vitamin D represents a
simple, safe and cost effective strategy to attenuate age-related
bone loss.
VITAMIN D AND FRACTURE RISK
Most of the intervention trials examining whether vitamin D and
calcium supplementation alone or in combination can reduce the risk
of fractures have focused on elderly women, with contrasting results.
A detailed summary of these findings are provided in several recent
comprehensive reviews (19, 20). However, in older men the anti-
fracture efficacy of these supplements remains uncertain due to the
lack of well-designed long-term clinical trials. In a factorial cluster-
randomized trial of 9605 community dwelling men and women aged
66+ years, Larsen et al. (21) reported that 1000 mg/d of calcium
carbonate and 400 IU/d of vitamin D3 was effective for reducing the
risk of fracture in females [relative risk (RR) 0.78, 95% CI 0.63-0.96]
but not in males. However, the number of fractures that occurred in
men in this study was small. Because of the limited data available in
men, we provide a brief summary of the findings from meta-analyses
which have evaluated the effects of vitamin D or vitamin D plus
calcium on preventing fractures in postmenopausal women or both
genders combined. 
For vitamin D alone, a comprehensive meta-analysis published in
2002 reported that it reduced the risk of vertebral fractures by 37%
(RR 0.63, 95% CI 0.45–0.88), with a trend towards a reduction in
non-vertebral fractures (RR 0.77, 95% CI 0.57–1.04, P=0.09) (22). A
more recent meta-analysis of RCTs reported that a vitamin D dose of
700-800 IU/d, but not <400 IU/d, reduced the risk of hip fracture by
26% (RR 0.74, 95% CI 0.61-0.88) and any non-vertebral fracture by
23% (RR 0.77, 95% CI, 0.68-0.87) compared to calcium or placebo
(23). In a subsequent meta-analysis and follow-up to this study,
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supplementation with <400 IU/d has little effect on preventing falls or
fractures, whereas a daily vitamin D3 dose of 700-1000 IU (or
100,000 IU every 4 months) appears to be both safe and effective for
reducing both falls and fracture risk in free living and institutionalized
elderly subjects (5, 23, 25, 26, 32). 
CONCLUSION
Vitamin D deficiency is a prevalent and serious public health problem
affecting the elderly. However, further studies are needed to define
the prevalence of this condition in elderly men, and the optimal serum
25(OH)D level or supplementation dose required to enhance BMD
and muscle function or prevent falls and fractures in this group. While
we await the outcome of further long-term RCTs, physicians and
health professionals should rely on the findings from recent scientific
trials in elderly women which indicate that daily supplementation with
800 IU or more of vitamin D3 (or a dose required to raise serum
25(OH)D levels to at 75-80 nmol/L) and 1200 mg of calcium appears
most effective for reducing falls and fractures, particularly in those
who are institutionalized, have low circulating 25(OH)D levels and/or
low BMD and impaired muscle function. As further targeted research
is conducted concerning the potential beneficial effects of vitamin D
on musculoskeletal health in men, it is important that we continue to
increase awareness, both in the community and amongst health
professionals, to screen and treat this disorder in both men and
women.
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human muscle tissue (5), and that with advancing age there is a
decrease in the number of VDRs in the muscle (5). A number of
RCTs in older women have also shown that vitamin D
supplementation (or combined vitamin D and calcium) can improve
lower extremity muscle performance, including body sway, muscle
strength, and timed up-and-go (28,29,30). While there are few
clinical trials in older men, one study in 65 healthy community
dwell ing men aged 65-87 years found that 6 months of
supplementation with cholecalciferol (1000 IU/d) did not improve
muscle strength, muscle power, or any measure of physical
performance (31). However, the men in this study were highly
functional with adequate serum 25(OH) D levels at baseline [mean
66 nmol/L]. In community dwelling and institutionalized elderly
people, there is compelling data from RCTs and a meta-analysis
showing that vitamin D therapy can reduce the likelihood of falls (29,
32, 33). A 2004 meta-analysis reported that supplementation with
vitamin D lowered the risk of falling by 22% (32). In one of the few
trials which examined older (>65 years) men and women separately,
Bischoff-Ferrari et al (33) found that 3 years of supplementation with
cholecalciferol (700 IU/d) and calcium (500 mg/d) significantly
reduced the odds of falling in women [Odd Ratio (OR) 0.54; 95%CI
0.30-0.97] but not men (OR 0.93; 95%CI 0.50-1.72). However,
further per protocol analysis revealed that among less active men
who adhered to the treatment, the odds of falling was markedly
reduced, but this was not significant (OR 0.65, 95% CI 0.18-2.29).
The authors attributed the lack of a significant beneficial effect of the
supplementation in men to higher physical activity and higher serum
25(OH) D levels relative to women. In light of the limited data
available in men, further long-term RCTs in ‘at risk’ groups of men
are needed before specific treatment guidelines can be formulated
with regard to the role of vitamin D for improving muscle function or
preventing falls in elderly men. 
VITAMIN D – IS THERE AN OPTIMAL LEVEL AND
DOSE FOR ELDERLY MEN? 
In older men, there is currently insufficient data concerning the
optimal level of serum 25(OH) D or dose of vitamin D to enhance
musculoskeletal health and function. However, several recent
comprehensive reviews based on the data from studies conducted
largely in women have provided an important insight into these
clinically relevant questions (5). There is now a growing consensus
that a serum 25(OH) D level of around 75-80 nmol/L is optimal for
musculoskeletal health benefits. This is supported by data showing
that: i) calcium absorption eff iciency and the rise in serum
parathyroid hormone (PTH) plateau at a serum 25(OH) D
concentration of ~80 nmol/L (34), and ii) the findings from meta-
analyses evaluating the effects of vitamin D supplementation on
BMD, fracture risk and falls risk (23, 31) showing that a serum
25(OH) D level of >75 nmol/L was required to see any beneficial
effects. In terms of defining the optimal dose of vitamin D, this has
been more challenging because there are many influential factors,
including basal serum 25(OH)D levels, body composition, seasonal
variation, and issues with compliance and the type of supplement
prescribed (vitamin D3 or D2). The fat soluble vitamin D mainly
occurs in two forms: ergocalciferol (activated ergosterol, vitamin D2),
found in plants and irradiated yeast; and cholecalciferol (activated 7-
dehydrocholesterol, vitamin D3) formed in human skin after exposure
to ultraviolet B (UVB) rays from the sun. It has been reported that
vitamin D2 may be less potent with less sustained elevation of
25(OH)D levels compared to vitamin D3 (35), but further studies are
needed to compare the anti fracture efficacy of D2 and D3. With
regard to the optimal dose of vitamin D to raise serum 25(OH) D
levels to at least 75 nmol/L, a recent prospective double blind RCT
reported that a daily dose of 3800 IU of vitamin D3 was necessary for
those with serum 25(OH) D above a threshold of 55 nmol/L and a
daily dose of 5000 IU was required for those below this threshold
(36). Furthermore, the current l i terature indicates that
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